OVARIAN CANCER

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers such as breast, kidney, ovarian, head and neck, colorectal, lung, and skin cancer. The main goal was to check safety and find the right dose. The …

This study tested a new radioactive drug, [225Ac]-FPI-1434, in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited. It involved 78 partic…

This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…

This study looked at two drug combinations to keep ovarian cancer from coming back in patients whose cancer had responded to initial treatment. The plan was to enroll 70 people, but only 5 joined before the study was stopped. Participants took either three drugs (apatinib, fluzop…

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced endometrial or ovarian cancers that are hormone receptor-positive and have certain gene changes (PI3K/PTEN). The goal was to see if the combination was safe and effective. Only 7 peo…

This study tested a new drug, luveltamab tazevibulin, against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum-based treatment. The drug targets a protein called FOLR1 found on cancer cells. The trial was terminated early, so results …

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had stopped responding …

This early-stage study tested an experimental drug called BLU-222 in 50 people with advanced solid tumors (like breast, ovarian, or stomach cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The st…

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combination could shrink tumors. The study was stopped early, and participants were expected to need ongoing…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested three different doses of an experimental drug called AUR 109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. Howeve…

This study tested whether combining two drugs, alpelisib and olaparib, works better than standard chemotherapy for people with a certain type of advanced ovarian cancer that no longer responds to platinum-based treatments. Participants had high-grade serous ovarian cancer without…

This early-phase study tested a new treatment for women with ovarian, fallopian tube, or peritoneal cancer that came back or didn't respond to standard chemotherapy. The approach involved taking a type of white blood cell (monocytes) from each participant, activating them with tw…

This early-phase study tested a new drug called PHN-010 in 26 people with advanced solid tumors (lung, colon, endometrial, ovarian, or cervical cancer) that had already been treated with at least one prior therapy. The drug is an antibody-drug conjugate designed to deliver a toxi…

This early-stage trial tested a new drug (STRO-002) combined with bevacizumab in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the best dose. The study was terminated, so results are limited.

This early-stage study tested an experimental drug called INCB062079 in 25 people with advanced liver cancer (hepatocellular carcinoma) and several other solid tumors. The main goal was to check the drug's safety and find the highest dose people could tolerate. The study was term…

This study tested a new drug called NUV-868, alone or combined with other cancer drugs (olaparib or enzalutamide), in people with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The study was…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This study looked at 289 people with early-onset breast, ovarian, colorectal, or pediatric cancers, plus those with multiple tumors. Researchers used a special test to check 200 genes for inherited mutations that standard tests might miss. The goal was to better understand why th…

This study aimed to measure how platinum resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers planned to use questionnaires to assess symptoms, daily challenges, and work productivity. The study was terminated early, but its…

This study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about how cancer works, not to test a new treatment. The information gathered may help researchers develop better ways to fight cancer in the future.